Age and adverse drug reactions from psychopharmacological treatment: data from the AMSP drug surveillance programme in Switzerland.


Autoria(s): Greil W.; Häberle A.; Schuhmann T.; Grohmann R.; Baumann Pierre
Data(s)

2013

Resumo

QUESTION UNDER STUDY: The frequency of severe adverse drug reactions (ADRs) from psychotropic drugs was investigated in hospitalised psychiatric patients in relation to their age. Specifically, the incidence of ADRs in patients up to 60 years was compared to that of patients older than 60 years. METHODS: Prescription rates of psychotropic drugs and reports of severe ADRs were collected in psychiatric hospitals in Switzerland between 2001 and 2010. The data stem from the drug surveillance programme AMSP. RESULTS: A total of 699 patients exhibited severe ADRs: 517 out of 28,282 patients up to 60 years (1.8%); 182 out of 11,446 elderly patients (1.6%, ns). Logistic regression analyses showed a significantly negative relationship between the incidence of ADRs and patients' age in general and in particular for weight gain, extrapyramidal motor system (EPMS) symptoms, increased liver enzymes and galactorrhoea. A significantly negative relationship was observed for age and the dosages of olanzapine, quetiapine, risperidone, valproic acid and lamotrigine. When comparing age groups, frequency of ADRs was lower in general for antipsychotic drugs and anticonvulsants, in particular for valproic acid in the elderly. Weight gain was found to be lower in the elderly for antipsychotic drugs, in particular for olanzapine. For the group of mood-stabilising anticonvulsants (carbamazepine, lamotrigine and valproic acid) the elderly exhibited a lower incidence of reported allergic skin reactions. CONCLUSION: The results suggest that for psychiatric inpatients the incidence of common severe ADRs (e.g., weight gain or EPMS symptoms) arising from psychotropic medication decreases with the age of patients.

Identificador

http://serval.unil.ch/?id=serval:BIB_7A2280A472CE

isbn:1424-3997 (Electronic)

pmid:23821346

doi:10.4414/smw.2013.13772

isiid:000321947500002

http://my.unil.ch/serval/document/BIB_7A2280A472CE.pdf

http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_7A2280A472CE2

Idioma(s)

en

Direitos

info:eu-repo/semantics/openAccess

Fonte

Swiss Medical Weekly, vol. 143, pp. w13772

Palavras-Chave #Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Aged, 80 and over; Antimanic Agents/adverse effects; Antipsychotic Agents/adverse effects; Basal Ganglia Diseases/chemically induced; Basal Ganglia Diseases/epidemiology; Benzodiazepines/adverse effects; Carbamazepine/adverse effects; Causality; Dibenzothiazepines/adverse effects; Drug-Related Side Effects and Adverse Reactions/epidemiology; Female; Galactorrhea/chemically induced; Galactorrhea/epidemiology; Humans; Logistic Models; Male; Middle Aged; Neuroleptic Malignant Syndrome/epidemiology; Risperidone/adverse effects; Severity of Illness Index; Switzerland/epidemiology; Triazines/adverse effects; Valproic Acid/adverse effects; Weight Gain; Young Adult
Tipo

info:eu-repo/semantics/article

article